Pharma BD Deal Intelligence
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →Reported Calithera shares spiked on the deal announcement, characterizing it as transformational financing and external validation of the arginase mechanism.
Calithera announced it would opt out of the INCB001158 co-development obligations and refocus on internal programs, signaling internal deprioritization of the…
Reported Calithera's termination of the 2017 collaboration effective September 30, 2020 amid a milestone-payment dispute, with Incyte taking over full global…
Source summaries from our enrichment pipeline; follow links for originals.
All 6 sources with sentiment breakdown →
Incyte and Calithera entered a global collaboration and license agreement for CB-1158, a first-in-class oral small-molecule arginase inhibitor. Calithera received $53M upfront ($45M cash + $8M equity), plus up to $750M in development, regulatory and sales milestones; 70/30 global development cost split (Incyte/Calithera) with 60/40 U.S. profit share. Strategic intent: combine with anti-PD-1 to overcome arginine-mediated immunosuppression.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Incyte Corporation / Calithera Biosciences, Inc. (this deal) | 2017 | $803M | — |
| Incyte Corporation / MacroGenics, Inc. | 2017 | $900M | 69 |
| Incyte Corporation / Vega Therapeutics, Inc. | 2026 | $2.0B | 68 |
| Incyte Corporation / Merus N.V. | 2017 | $3.0B | 35 |
| Incyte Corporation / Genesis Molecular AI, Inc. | 2026 | $1.0B | — |
| Incyte Corporation / Escient Pharmaceuticals Inc. | 2024 | $750M | — |
| Amgen Inc. / Micromet Inc. | 2012 | $1.2B | 88 |
← Browse all deals · How we score deals
More: 2017 deals · Incyte Corporation deals · Hematology deals